PEAK6 Group’s Sarepta Therapeutics SRPT Stock Holding History

PEAK6 Group’s Portfolio SRPT Stock Details SRPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2013 Q4	–	Sell	-4,000	Closed	-$94.1K	–	5415
2013 Q3	$94.1K	Buy	+4,000	New	+$154K	﹤0.01%	4231

Other funds holding SRPT

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

FAM

Fred Alger Management New York $22.8B AUM 64.63% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

GGHC

Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return

PEAK6 Group's SRPT Position: Q4 2013 in Review

PEAK6 Group sold out of Sarepta Therapeutics (SRPT) in Q4 2013, closing a stake of 4,000 shares — an estimated $94.1K sold.

PEAK6 Group first reported a position in SRPT in Q3 2013 and held it in 1 quarter. The position peaked at $94.1K in Q3 2013. 108 funds tracked by Wall St. Rank hold SRPT as of Q4 2013.

PEAK6 Group reported no remaining Sarepta Therapeutics position as of Q4 2013 after selling out during the quarter.
PEAK6 Group sold 4,000 Sarepta Therapeutics shares in Q4 2013, an estimated $94.1K.
PEAK6 Group first reported a position in Sarepta Therapeutics in Q3 2013 and held it in 1 quarter.
PEAK6 Group's Sarepta Therapeutics position peaked at $94.1K in Q3 2013.
108 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q4 2013.

Based on PEAK6 Group's 13F filing for Q4 2013, filed 13 Feb 2014.